ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO842

Tolvaptan Slows the Decline of Renal Function in Autosomal Dominant Polycystic Kidney Disease Independent of the Response to Total Kidney Volume: Analysis of the TEMPO 3:4 Japanese Cohort

Session Information

Category: Genetic Diseases of the Kidneys

  • 1001 Genetic Diseases of the Kidneys: Cystic

Authors

  • Horie, Shigeo, Juntendo University, Tokyo, Japan
  • Muto, Satoru, Juntendo University, Tokyo, Japan
  • Kawano, Haruna, Juntendo university, Tokyo, Japan
  • Okada, Tadashi, Otsuka Pharmaceutical Co., Ltd., Osaka, Japan
  • Shibasaki, Yoshiyuki, Otsuka Pharmaceutical Co., Ltd., Osaka, Japan
  • Ibuki, Tatsuki, Otsuka Pharmaceutical, Tokushima, Japan
Background

In TEMPO 3:4 (NCT00428948), TLV slowed the increase in TKV and renal function decline over a 3-year period in patients with ADPKD. We conducted a post-hoc analysis of TEMPO 3:4 in the Japanese cohort to determine if there was an association between change in TKV and renal function in patients treated with tolvaptan.

Methods

The TLV-treated group of the Japanese cohort of TEMPO 3:4 was subdivided into responders (R; net TKV decrease) and non-responders (NR; net TKV increase) at Year 3. An analysis of potential correlations between TLV treatment and the effects on TKV and eGFR were performed.

Results

147 patients (placebo (PBO): 55; TLV : 92 [R: 37; NR: 55]) were analyzed. At Year 3, the mean changes in TKV for PBO, TLV R, and TLV NR were 16.99%, -8.33% and 13.95%; mean changes in eGFR were -12.61, -8.47 and -8.58 mL/min/1.73 m2. Female gender was a significant predictive factor for TLV inhibition of TKV growth. Compared with PBO, eGFR decline was significantly reduced in both R and NR groups (P<0.05), however, no difference was seen between R and NR. No difference in urine osmolality at Year 1, 2, and 3 was observed between R and NR.

Conclusion

TLV slowed the decline in renal function over a 3-year period in the Japanese cohort of patients irrespective to the effect of TLV on TKV. TLV treatment should not be terminated by the short-time growth of TKV.

Funding

  • Commercial Support